Study S000722

A Single -Center, Randomized, Double-blind, Placebo-controlled Proof of Exploratory Study Evaluating the Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

ClinicalTrials.gov record

Registration

Registration: NCT07570810
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: TRIPLE
Status: NOT_YET_RECRUITING
Enrollment: 30
Start: 2026-06-01
Primary completion: 2026-11-30
Lead sponsor: Shanghai Jiao Tong University School of Medicine
Conditions: Type 2 Diabetes; Obesity; Non-alcoholic Fatty Liver Disease
Interventions: DRUG:CS0159; DRUG:CS0159 placebo; DRUG:Semaglutide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percentage change in body weight relative to baseline [Baseline to 12 weeks]
Changes in energy expenditure [Baseline to 12 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.